A Phase 1 interventional study of Part 1; LOU064 (Remibrutinib) and Part 2; LOU064 (Remibrutinib) in Hepatic Impairment, sponsored by Novartis Pharmaceuticals. Completed at 1 site in Hungary. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This was a Phase 1, open-label study to evaluate the PK, safety, and tolerability after administration of multiple doses of remibrutinib in participants with mild, moderate, or severe hepatic impairment (HI) compared to pooled matched healthy control participants with normal hepatic function.
This study was conducted in 2 parts. Part 1 was comprised of participants with mild (Child Pugh A; Group 1) and moderate (Child-Pugh B; Group 2) HI and matched healthy control participants with normal hepatic function (Group 4). Groups 1 and 2 were enrolled in parallel. Part 2 was comprised of participants with severe HI (Child-Pugh C; Group 3) and matched healthy control participants with normal hepatic function (Group 4). Matched healthy control participants (Group 4) were enrolled in parallel to Parts 1 and 2.
Up to 48 male and female participants, aged 18 to 70 years inclusive, were planned to be enrolled, with 8 participants enrolled in each of the mild (Child-Pugh A; Group 1 in Part 1), moderate (Child Pugh B; Group 2 in Part 1), and severe (Child-Pugh C; Group 3 in Part 2) HI groups, and up to 24 participants planned to be enrolled in the matched healthy control group (Group 4 from Parts 1 and 2). Additional participant(s) may have been enrolled if a participant discontinued from the study before completion of the PK assessment to ensure that at least 6 participants in each group completed the scheduled PK assessments. Due to difficulties in enrolling severe HI participants, only 7 severe HI participants were enrolled in this study.
Each study part was comprised of a screening period of up to 28 days (Day -29 to Day -2), a Baseline evaluation on Day -1, and a treatment period including up to 8 days of safety and PK data collection. Participants who met the eligibility criteria at Screening were admitted for Baseline evaluations on Day 1. Baseline safety assessments were performed prior to first dosing of study treatment. Participants were domiciled from Day -1 through Day 8.
All participants received 25 mg remibrutinib b.i.d. orally under fasting conditions on Days 1 and 2, and a morning oral dose of 25 mg remibrutinib on Day 3. PK samples were collected predose on Day 3 and until 72 hours post Day 3 dosing. Throughout the study, safety assessments included physical examinations, electrocardiograms (ECGs), vital signs, clinical laboratory evaluations (hematology, chemistry, urinalysis, and coagulation), and AE/serious adverse event (SAE) monitoring.
The investigator and Novartis conducted a joint interim review of safety and PK data from Part 1 before proceeding to Part 2. Data from at least 4 participants with mild HI (Group 1), 4 participants with moderate HI (Group 2), and their matched healthy control participants (Group 4), who completed PK study assessments up to Day 6 in Part 1, were evaluated.
Part 2 only began after administration of remibrutinib in the 4 evaluable participants from each of the mild and moderate HI groups (Groups 1 and 2) and their matched healthy control participants (Group 4) in Part 1 was deemed safe and tolerable based on the interim review by the investigator and Novartis. Depending on the outcome of the interim review, administration of a lower dose of remibrutinib in severe HI participants (Group 3) and their matched healthy control participants was to be considered. However, upon review of the interim data, the decision was made to not change the dose for severe HI participants.
As per the current study protocol, study drug strengths available for this trial were 25 mg and 10 mg. Therefore, the lowest dose that could have been used in Part 2 was 10 mg b.i.d. At the time of the interim data review, a decision was to be made as to whether or not to reduce the Part 2 dose, based on observed PK exposures and safety assessments in Part 1 and predicted exposures in severe HI participants in Part 2. In this particular case, Part 2 was to be initiated after the submission and approval of a Substantial Amendment from the respective Health Authorities (HA) and Ethics Committee (EC) were obtained. A decision was made to proceed with Part 2 using the same 25 mg dose as in Part 1.
Study Completion evaluations occurred on Day 8, followed by a post-study safety follow-up contact (e.g., follow-up telephone call, e-mail) approximately 30 days after last administration of study treatment. The information collected during the follow-up contact was kept as source documentation. The study was considered completed once all the participants finished the required assessments.
The total study duration for each participant was expected to be up to approximately 62 days, including the Screening period and the follow-up contact.
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All participants
Must have been able to communicate well with the investigator and to understand and comply with the requirements of the study.
Participants with mild, moderate, and severe HI (Groups 1, 2 and 3)
Seated vital signs must have been within the following ranges at Screening and Baseline:
Had impaired hepatic function as defined by the classification for severity of liver disease and had a Child-Pugh score in line with one of the following HI groups at Screening:
Participants with other stable medical disorders such as controlled diabetes, hyperlipidemia, hypothyroidism, etc., may have been eligible as long as they were considered appropriate for enrollment as determined by the investigator by past medical history, physical examination, , and clinical laboratory tests at Screening.
Healthy control participants (Group 4)
Seated vital signs must have been within the following ranges at Screening and Baseline:
Exclusion Criteria:
All participants
Regular use of caffeine or methyl xanthine-containing products exceeding 800 mg (\~4 cups of coffee containing 200 mg caffeine per cup) per day.
Participants with mild and moderate HI (Groups 1 and 2)
Abnormal clinical laboratory values for any of the following parameters at Screening or Baseline:
Presence of moderate to severe impaired renal function as indicated by any of the following at Screening:
Clinically significant illness within 2 weeks prior to first dosing that could have jeopardized safety of the study participant and/or altered the study results as judged by the investigator.
Participants with severe HI (Group 3)
Abnormal clinical laboratory values for any of the following parameters at Screening or Baseline:
Presence of moderate to severe impaired renal function as indicated by any of the following at Screening:
Clinically significant illness within 2 weeks prior to first dosing that could have jeopardized safety of the study participant and/or altered the study results as judged by the investigator.
Healthy control participants (Group 4)
In the case where a safety laboratory assessment at Screening or Baseline was outside of the range specified above, the assessment may have been repeated once at Screening and/or once at Baseline. If the repeat value remained outside of the specified ranges, the participant was excluded from the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Mild and Moderate HI participants and matching healthy participants
Drug: Part 1; LOU064 (Remibrutinib)
Severe HI participants and matching healthy participants
Drug: Part 2; LOU064 (Remibrutinib)
25 mg remibrutinib (2.5 days)
25 mg remibrutinib (2.5 days)
Cmax,ss
The maximum (peak) observed blood concentration following multiple-dose administration (mass/volume)
Time frame: 72 hours
AUCtau
The area under the curve (AUC) from time zero to the end of the dosing interval tau (12 hours) following multiple-dose administration
Time frame: 72 hours
AUClast,ss
The area under the curve (AUC) from time zero to the last measurable blood concentration sampling time (Tlast) following multiple-dose administration (mass\*time/volume)
Time frame: 72 hours
Tmax,ss
The time to reach maximum (peak) blood concentration following multiple-dose administration (time)
Time frame: 72 hours
T1/2
The elimination half-life associated with the terminal slope (lambda\_z) of a semi logarithmic concentration-time curve (time)
Time frame: 72 hours
Number of participants with adverse events
The distribution of adverse events was done via the analysis of frequencies for Adverse Event (AEs) and Serious Adverse Event (SAEs), through the monitoring of relevant clinical and laboratory safety parameters.
Time frame: 8 days
Unbound fraction; Cmax,ss,u
The maximum (peak) observed unbound plasma concentration following multiple-dose administration (mass/volume)
Time frame: 8 days
Unbound fraction; AUCtau,u
The unbound plasma AUC from time zero to the end of the dosing interval tau (12 hours) following multiple-dose administration
Time frame: 8 days
Unbound fraction; AUClast,ss,u
The area under the curve (AUC) from time zero to the last measurable unbound plasma concentration sampling time (Tlast) following multiple-dose administration (mass\*time/volume)
Time frame: 8 days
Plan to share: No
Ran from Oct 2022 to primary completion in Dec 2023, 13 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Remibrutinib